Fluid attenuation in non‐contrast‐enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma
- 4 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 152 (3), 523-531
- https://doi.org/10.1007/s11060-021-03720-y
Abstract
The WHO 2016 update classifies glioblastomas (WHO grade IV) according to isocitrate dehydrogenase (IDH) gene mutation status. We aimed to determine MRI-based metrics for predicting IDH mutation in glioblastoma.Keywords
This publication has 60 references indexed in Scilit:
- Cystic GlioblastomaNeurosurgery, 2014
- IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionNeuro-Oncology, 2013
- Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase MutationsClinical Cancer Research, 2013
- The Definition of Primary and Secondary GlioblastomaClinical Cancer Research, 2013
- Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in GlioblastomaAmerican Journal of Neuroradiology, 2012
- Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of OriginJournal of Clinical Oncology, 2011
- Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain TumorsBrain Pathology, 2009
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Cystic glioblastoma multiforme: survival outcomes in 22 casesJournal of Neurosurgery, 2004